NCT03356587 2017-11-29A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based TherapySeoul National University HospitalPhase 2 Unknown32 enrolled